Mumbai, December 16, 2025: Global pharma major Lupin Limited (Lupin) today announced that its greenhouse gas (GHG) emissions reduction targets have been officially validated by the Science Based Targets initiative (SBTi). These validations cover all three emission scopes – Scope 1, Scope 2, and Scope 3 – aligning with the Paris Agreement to limit global temperature rise to 1.5°C.

This milestone underscores Lupin’s commitment to sustainability and decisive climate action, positioning the company among a select group that has achieved comprehensive SBTi validation within a year of setting its climate targets.

Key short-term targets:

• Reduce absolute Scope 1 and 2 greenhouse gas emissions by 42.0% by FY 2030, with FY 2023 as the base year.
• Reduce Scope 3 greenhouse gas emissions by 61.07% by FY 2033, across purchased goods and services, fuel- and energy-related activities, upstream and downstream transportation and distribution, business travel, employee commuting, processing and use of sold products, and franchises, using FY 2024 as the baseline.

These goals are aligned with the 1.5°C pathway and validated under SBTi’s latest guidelines, thereby positioning Lupin as a key participant in the global effort to combat climate change.

Ramesh Swaminathan, Executive Director, Global CFO, and Head of IT and API Plus SBU, Lupin, said, “The validation from SBTi underscores Lupin’s unwavering commitment to reducing greenhouse gas emissions through a rigorous, science-driven approach. By setting ambitious targets, we are embedding sustainability into both our financial and operational strategies. These goals guide investments in renewable energy, energy efficiency, and low-carbon technologies across our global operations. Proactive action on climate change is essential not only for mitigating risks and optimising costs but also for unlocking opportunities for innovation and long-term growth.”

About Science-Based Targets initiative
The Science Based Targets initiative (SBTi) defines and promotes best practice in science-based target setting and independently assesses companies’ targets. To know more, visit https://sciencebasedtargets.org/

About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
To know more, visit www.lupin.com  or follow us on LinkedIn https://www.linkedin.com/company/lupin

For further information or queries, please contact
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
rajalakshmiazariah@lupin.com